News

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty
Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...
Biocon Biologics gets USFDA nod for diabetes medication
Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...
Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...
Biocon Biologics gets USFDA nod for rapid-acting insulin
The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...
The Pharma Letter2d
FDA approves Biocon BLA for Kirsty
The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...
Should you buy Biocon shares as USFDA gives approval to diabetes drug?
Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...
Capital Market on MSN2d
Biocon arm gets USFDA approval for insulin, Kirsty
Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...
Trade Brains on MSN2d
Pharma stock jumps 4% after receiving USFDA approval for diabetes treatment drug
The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...
Medical Dialogues2d
Biocon Biologics expands biosimilar insulin portfolio with USFDA nod of Kirsty
Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...
CNBCTV182d
Biocon shares near 52-week high after USFDA approves key diabetes treatment drug
Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...
The Bakersfield Californian2d
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only ...
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE ...